CURRENT
ISSUE
1566

The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.

EPINEPHRINE AUTO-INJECTORS — EpiPen and EpiPen Jr, which are also available generically, have been used effectively for treatment of anaphylaxis...  Continue reading

More from Issue 1566
Previous Issue: 1565      February 11, 2019
Coming Soon
Drugs for Gout
Rifamycin (Aemcolo) for Treatment of Travelers’ Diarrhea
Xyosted: A Testosterone Auto-Injector for Hypogonadism
Ozenoxacin Cream (Xepi) for Impetigo
Fluticasone Propionate (Xhance) for Nasal Polyps
Drugs for Heart Failure
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1566

Since 2008, because of safety concerns, the FDA has mandated long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes.1 Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.2-4

STANDARD TREATMENT — Metformin (Glucophage, and others) is the drug of choice for initial treatment of type 2 diabetes.5 For patients who do not achieve their A1C goal with metformin, the choice of an additional drug varies with the ... Continue reading